NASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $13.09 +0.11 (+0.85%) As of 10:32 AM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsInsider TradesSEC FilingsTrends About Palvella Therapeutics Stock (NASDAQ:PVLA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$12.55▼$13.1850-Day Range N/A52-Week Range$6.20▼$22.32Volume3,809 shsAverage Volume48,722 shsMarket Capitalization$17.28 millionP/E RatioN/ADividend YieldN/APrice Target$38.00Consensus RatingBuy Company OverviewRead More… Palvella Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPalvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PVLA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PVLA. News and Social Media3.1 / 5News Sentiment0.65 News SentimentPalvella Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Palvella Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for PVLA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,720.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.39% of the stock of Palvella Therapeutics is held by insiders.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PVLA Stock News HeadlinesInsider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Buys 4,000 Shares of StockDecember 20, 2024 | insidertrades.comPalvella Therapeutics, Inc. (PVLA)January 14 at 5:42 PM | finance.yahoo.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.January 15, 2025 | Crypto Swap Profits (Ad)Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC WainwrightJanuary 12 at 3:22 AM | americanbankingnews.comPalvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic DiseaseJanuary 12 at 1:39 AM | msn.comBuy Rating Affirmed for Palvella Therapeutics Amid Clinical Progress and Strong Financial PositionJanuary 10, 2025 | markets.businessinsider.comPalvella Therapeutics announces results from Phase 2 study of QTORINJanuary 10, 2025 | markets.businessinsider.comPalvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM TreatmentJanuary 9, 2025 | msn.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $12.00 at the start of the year. Since then, PVLA shares have increased by 10.8% and is now trading at $13.30. View the best growth stocks for 2025 here. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:PVLA CUSIPN/A CIK1583648 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$38.00 Low Stock Price Target$38.00 Potential Upside/Downside+185.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,320,000Free FloatN/AMarket Cap$17.56 million OptionableN/A Beta0.67 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:PVLA) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.